BACTERIA ISOLATION FROM STOOLS COLLECTED FROM CENTENARIANS PEOPLE
NCT ID: NCT05701371
Last Updated: 2024-03-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
20 participants
OBSERVATIONAL
2023-06-06
2023-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The review of the literature shows that certain species present among centenarians have an interest in maintaining the longevity of these individuals. Numerous studies have shown that the intestinal microbiota of centenarians presents a greater diversity compared to groups of younger subjects as well as an enrichment in certain bacteria such as Akkermansia and Christensenella.
The goal of this observational study is to constitute a biological samples collection from centenarian people, to proceed with the isolation of beneficial commensal strains such as Faecalibacterium prausnitzii, Akkermansia muciniphila and Oscillospiraceae, in a non-limitative way.
Elderly and centenarian people will be recruited in nursing home among the Gerontopole of "Ile de France" network.
Blood (serum + TruCulture tubes) and stools will be collected from each subject.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Effect of Probiotics on Aging Population
NCT04911556
Behavior of Various Galenic Forms of a Probiotic in the Digestive Tract.
NCT03143400
A Pilot Study To Evaluate the Effects of Lactobacillus Supplements
NCT05520073
The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function And/or Faecal Microbiota Composition
NCT05355571
Probiotics in Elderly Patients With Medical Conditions
NCT04035616
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Centenarian cohort
Biological samples collection
blood drawing + feces collection in a dedicated device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological samples collection
blood drawing + feces collection in a dedicated device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 18.5 and 25 kg/m2
* Clinical exam normal
* Subject agreeing to participate in the study and not objecting to participate in the study.
* Able and willing to provide samples of blood and faeces
Exclusion Criteria
* Infectious gastrointestinal event within 3 months prior to inclusion
* Diabetes
* Severe chronic disease (active cancer, HIV, severe renal failure, ongoing severe heart or liver or biliary disorders, arthritis) or severe chronic disease deemed incompatible with the conduct of the study by the investigator
* Major surgical procedure likely to disrupt the intestinal microbiota, within 6 months prior to inclusion
* Recent food allergy \< 3 months prior to inclusion
* Antibiotic, antiviral, antifungal, proton pump inhibitor or any other treatment likely to disrupt the microbiota in the 3 months prior to inclusion
* Previous or current use of a treatment that may disrupt the microbiota (e.g. laxatives, antidiarrheals, antacids...) in the last 3 months
* Significant change in dietary habits or physical activities in the 3 months prior to inclusion
* Consumption of more than 2 standard glasses of alcoholic beverages per day
* Smoking \> 20 cigarettes per day, illicit drug use,
* Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)
* Severe psychiatric or neurological pathology
* Completely dependent subject (GIR Score = 1)
* Subject with liquid stools (Bristol Score = 7) or very hard stools (Bristol Score = 1)
* Vaccination in the last month before inclusion
* Subject unable to understand the purpose of the research, answer questions and give their decision to participate in the study
* Subject already included in another research study involving the human subject
* Subject under guardianship and whose guardianship objects to the participation of his/her protectee,
* Subject not affiliated with a social security plan or not a beneficiary of such a plan
95 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bioaster
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cyril GUYARD
Role: STUDY_DIRECTOR
Bioaster
Olivier HANON
Role: PRINCIPAL_INVESTIGATOR
Gérond'if
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gerond'if - Gérontopôle Ile de France
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A02293-40
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.